Suraxavir trial finds faster flu recovery times for male but not female users
A single 40-mg dose of the antiviral drug suraxavir marboxil significantly shortened flu symptom resolution time in male ...
Flu antiviral baloxavir shows promise over other treatments for high-risk patients, shortening symptom duration
A systematic review and meta-analysis led by Shandong University in China has evaluated the comparative efficacy and safety of antiviral medications for treating nonsevere influenza. Findings indicate ...
Biomednewsbreaks Calidi Biotherapeutics Inc. (NYSE American: CLDI) To Present Breakthrough Virotherapy Platform At AACR 2025
Calidi Biotherapeutics (NYSE American: CLDI) , a clinical-stage biotechnology company specializing in targeted antitumor virotherapies, announced it ...
Investornewsbreaks Nanoviricides (NYSE American: NNVC) To Present Broad-Spectrum Antiviral Innovations At Biotech Showcase 2025
NanoViricides, Inc. (NYSE American: NNVC) , a clinical-stage company developing antiviral drugs designed to resist <a target=_blank href=https:// ...